These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9838551)

  • 21. Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor.
    Choc MG; Mueller EA; Robinson WT; Kumle A; Smith HT; Charnick SB
    Transplant Proc; 1998 Aug; 30(5):1664-5. PubMed ID: 9723234
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine.
    Andrysek T
    Mol Immunol; 2003 Jul; 39(17-18):1061-5. PubMed ID: 12835077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
    Lee KL; Lee KT; Chung HM; Lin YP
    Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545
    [No Abstract]   [Full Text] [Related]  

  • 24. Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets.
    Barr WH
    Transplant Proc; 1999 May; 31(3A Suppl):25S-30S. PubMed ID: 10330956
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
    Kees F; Bucher M; Schweda F; Gschaidmeier H; Burhenne J; Mikus G; Faerber L
    Ther Drug Monit; 2006 Jun; 28(3):312-20. PubMed ID: 16778713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients.
    Tarek BO; Nadia BF; Anis K; Saloua L; Abderrahmane A; Lamia T; Amel L; Mohamed L
    Transplant Proc; 2010 Nov; 42(9):3735-8. PubMed ID: 21094848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testing switchability of a new microemulsion formulation of cyclosporine.
    Talaulikar GS; Srishyla MV; Job V; Selvakumar R; Thomas PP
    Transplant Proc; 2003 Dec; 35(8):2899-901. PubMed ID: 14697932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
    Park K; Kim MS; Kim SI; Kim YS; Moon JI
    Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
    [No Abstract]   [Full Text] [Related]  

  • 29. Induction of immunosuppression by microemulsion cyclosporine in liver transplantation.
    Rasmussen A; Hjortrup A; Hansen B; Heslet L; Kirkegaard P
    Transplantation; 1996 Oct; 62(7):1031-3. PubMed ID: 8878402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence of Neoplanta capsule to Sandimmune Neoral, microemulsion formulations of cyclosporin A in human subjects.
    Lee YJ; Chung SJ; Shim CK
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):210-5. PubMed ID: 9587047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetic analysis of cyclosporine is essential for the management of refractory pure red cell aplasia.
    Kato Y; Tajima K; Suzuki I; Kohno K; Hiroshima Y; Kato T
    Ann Hematol; 2012 Dec; 91(12):1991-2. PubMed ID: 22836945
    [No Abstract]   [Full Text] [Related]  

  • 32. A generic cyclosporine development program.
    Schroeder TJ; Levy R; Pouletty P; First MR
    Transplant Proc; 1997; 29(1-2):1235-8. PubMed ID: 9123288
    [No Abstract]   [Full Text] [Related]  

  • 33. Improving the oral absorption of cyclosporine in malabsorbers: a review of the Neoral Compassionate Need Program.
    Mueller EA; Kovarik JM; Pittrow D
    Transplant Proc; 1998 Aug; 30(5):1691-3. PubMed ID: 9723246
    [No Abstract]   [Full Text] [Related]  

  • 34. Microemulsion formulation increases cyclosporin bioavailability in cystic fibrosis.
    Mikhail GW; Eadon H; Rogers P; Leaver N; Banner NR; Khaghani A; Yacoub MH
    Lancet; 1995 Dec; 346(8990):1638-9. PubMed ID: 7500788
    [No Abstract]   [Full Text] [Related]  

  • 35. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.
    Kovarik JM; Noe A; Wang Y; Mueller I; DeNucci G; Schmouder RL
    Eur J Clin Pharmacol; 2006 May; 62(5):361-6. PubMed ID: 16547714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients.
    Loss GE; Brady L; Grewal HP; Siegel CT; Mead J; Bruce DS; Cronin DC; Woodle ES; Newell KA; Thistlethwaite JR; Millis JM
    Transplant Proc; 1998 Jun; 30(4):1435-6. PubMed ID: 9636581
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of particle size distribution on bioavailability of cyclosporine: novel drug delivery system.
    Andrýsek T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):3-8. PubMed ID: 12426766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral.
    Kees F; Mair G; Dittmar M; Bucher M
    Transplant Proc; 2004 Dec; 36(10):3234-8. PubMed ID: 15686736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral.
    Ritschel WA
    Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption of cyclosporine (Neoral) from a microemulsion formulation in a living donor liver transplant recipient.
    Maeda Y; Kuzuya T; Ota S; Yamada K; Kobayashi T; Hayashi S; Yokoyama I; Nakao A; Nabeshima T
    Transplant Proc; 2002 Nov; 34(7):2784-7. PubMed ID: 12431611
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.